Please select the option that best describes you:
Do people extrapolate data from the NIAGARA trial regarding peri-operative durvalumab cisplatin based chemo to upper tract urothelial carcinoma?
Answer from: Medical Oncologist at Academic Institution
Currently, I am not using NIAGARA trial data for patients with upper tract urothelial carcinoma (since it was only for MIBC), but am very enthusiastic about the ongoing EA8192 phase II-III trial evaluating this critical question, details can be found in the link below (we highly encourage sites to o...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Currently, in my practice, I would not utilize NIAGARA data for patients with upper tract urothelial cancer. Patients with "primary non-bladder" cancers, i.e., those arising from the ureter, urethra, or renal pelvis, were excluded from the trial, even if they had urothelial histology. There are...